Liver diseases and disorders that cause the liver to function improperly or cease functioning and it is a major problem of worldwide proportions. Liver disease in general can be termed as the abnormal functioning of liver, which can be due to excessive alcohol consumption or a viral infection. Liver disease may have complex effects on drug clearance, biotransformation, and pharmacokinetics. Pathogenetic factors include alterations in intestinal absorption, plasma protein binding, hepatic extraction ratio, liver blood flow, portal-systemic shunting, biliary excretion, enterohepatic circulation, and renal clearance. Aging population increasing prevalence of liver diseases such as hepatitis and liver cancer coupled with elevated demand for vaccination programs and increasing healthcare-related consumer expenditure are driving the growth of global liver diseases therapeutic drugs market.
The global liver diseases therapeutic drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug classes (antiviral, chemotherapy, Corticosteroids, immunoglobulins, immunosupressants, targeted therapy drugs and vaccines), therapeutic applications (alcohol induced liver diseases, autoimmune liver disorders, hepatocellular carcinoma, NAFLD, viral or hepatitis liver disorders), and forecasts growth trends (CAGR% – 2017 to 2021).
The global liver diseases therapeutic drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global liver diseases therapeutic drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global liver diseases therapeutic drugs market and included in this report are Abbott Laboratories Astellas Pharma Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and F. Hoffmann-La Roche Ltd.